View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 19, 2022

Sirnaomics doses first subject in Phase I/II skin cancer drug trial

Determining the number of subjects with histological clearance of facial isSCC lesions after treatment is the primary endpoint.

Sirnaomics has dosed the first subject in the Phase I/II clinical trial of its RNAi therapeutic, STP705, to treat facial squamous cell skin cancer in situ (isSCC) patients.

The open-label, dose-escalation trial will assess the safety, tolerability, and efficacy of varying intralesional doses of STP705.

It will also aid in detecting the recommended drug dose.

The biomarkers linked to isSCC formation pathways, including TGF-β1 and COX-2, will be assessed in the trial.

The trial will enrol a total of 30 subjects into three trial cohorts. They will receive the drug once every week for a total of six weeks.

Cohort A will be given a 30μg dose while Cohort B and C will receive 60μg and 90μg doses, respectively.

Determining the number of subjects with histological clearance (HC) of facial isSCC lesions following STP705 treatment is the trial’s primary endpoint.

The company anticipates concluding the trial and reporting data in the first quarter of next year.

A lead candidate of the company, STP705 is a small interfering RNA (siRNA) drug.

Leveraging dual-targeted inhibitory properties and polypeptide nanoparticle-boosted delivery, it targets both TGF-β1 and COX2 gene expression.

Sirnaomics founder, board chairman, executive director, president, and CEO Dr Patrick Lu said: “We expect that the study of STP705 as a treatment for facial isSCC to yield positive results, given previous studies of STP705 that have shown to be safe and effective as a cancer treatment.

“Our drug has the potential to offer millions of patients with these non-melanoma facial lesions a non-surgical, non-invasive alternative to traditional lesion removal.”

In May this year, the company began a Phase I trial of STP705 in adult patients who undergo abdominoplasty for submental fat reduction.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena